Medical News
Addiction
Allergies
Alternative Medicine
Asthma
Cancer
Cardiology
Chiropractic
Dental
Dermatology
Diabetes
Emergency
Family Medicine
General
Geriatrics
Hospitals
Infectious Diseases
Internal Medicine
Managed Care / HMO
Medical Products
Mental Health
Neurology
Nursing
Nutrition
OB / GYN
Pediatrics
Pharmaceuticals
Physical Therapy
Plastic Surgery
Psychology
Radiology / Imaging
Research
Sports Medicine
Surgery
Vision

Xcelience Employs CFS1200 Capsule Filling and Sealing Machine

Xcelience's implementation of the CFS1200 will allow its formulation scientists the opportunity to accelerate the drug development timeframe.

Tampa, FL (PRWEB) March 14, 2007 -- Xcelience, LLC, has enhanced its services with the addition of the CFS1200 which allows formulation scientists the opportunity to accelerate the development timeframe. This is done by filling and sealing up to 1,200 capsules per hour with liquid or semi-solid formulations without banding.

This CFS1200 technology will benefit Xcelience's client base by facilitating rapid development and manufacturing of multiple strengths of simple liquid-filled capsule products. Xcelience can now leverage its expertise in the development of lipid formulations for very poorly soluble drugs by accelerating the delivery of enhanced-bioavailability products for animal and clinical studies. The CFS1200 also complements Xcelience's "Xcelodose™ 600 precision micro filling system," by accelerating the development and manufacturing of early-stage clinical supplies of drug which cannot be dosed as unformulated API. Xcelodose™ is a registered trademark of Capsugel BVBA.

"The addition of the CFS1200 further supplements Xcelience's capabilities and services for supporting early drug development," according to Xcelience Vice President, Randall H. Guthrie. "The flexibility in providing unique services to assist companies in advancing their drug candidates into human clinical services in an efficient manner is part of our strategic plan. We will continue to provide innovative thinking to this end in order to support our clients and for the good of drug development."

For more information, log on to www.xcelience.com
Contact:
Mike Nabors
Teasdale Worldwide
mike (at) teasdaleworldwide.com
(813) 868-1524

###

Simillar Articles

Xcelience Expands its Early Drug Development Capabilities
The Tampa-based CRO is first to acquire next generation Xcelodose.
Xcelience Expanding Operations
The Tampa-based contract research organization acquires a brand new building.
Xcelience Launches New Service to Enhance Its Preformulation & Formulation Capabilities
The Tampa-based CRO continues its perpetual growth with new XRD support
Xcelience Launches Drug Development Consulting Service
The launch of Xpert Consulting will provide supplemental services to assist clients.
Xcelience Debuts its Innovative and Interactive Forum: XpertXchange™
XpertXchange will initiate dialogue between Xcelience scientists and drug development professionals.
Home Terms of Use Privacy Policy Contact Us